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ABSTRACT 
Serum albumin is the most extensively studied of 
all proteins because of its availability, low cost, 
stability and ligand binding properties. It has the 
ability to bind a wide variety of ligands including 
bilirubin whose interaction with albumin is of 
physiological and clinical importance. 
The interaction of bilirubin with albumin has been 
studied by a variety of techniques i.e. fluorescence, 
peroxidase method, CD spectroscopy, equilibrium dialysis, 
ultrafiltration, microrate dialysis etc. Bilirubin is a 
non fluorescent molecule but it causes a quenching in 
the fluorescence after adding to albumin solution which 
is indicative of the binding of bilirubin to albumin. 
Binding constants has been determined earlier by various 
workers using fluorescence quenching method. In this 
dissertation data have been presented on the binding of 
bilirubin to albumin using a new approach i.e. 
fluorescence enhancement. Bovine serum albumin gave an 
emission spectrum in the wavelength range 300-400 nm 
when excited at 282 nm with emission maxima at 340 nm. 
Addition of bilirubin to albumin solution caused 
quenching in fluorescence at 340 nm. In addition to 
this phenomena, there was an appearance of fluorescence 
at 528 nm which increased on increasing bilirubin 
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concentration. Using this wavelength, excitation maxima 
was determined to be as 487 nm which was the absorption 
maximum of bilirubin-albumin complex. At low 
concentrations of albumin i.e. 1 pM and 2.5 juM, the 
fluorescence of bilirubin albumin complex increased 
linearly upto a molar ratio 1.0 and then it sloped off 
but if the albumin concentration was increased to 10 ;uM 
and 20 juM, the fluorescence at 528 nm increased linearly 
reaching to a maximum value around molar ratio 1.0 and 
then it decreased sharply which can be explained on the 
basis of structural perturbations in the albumin 
molecule brought about by the binding of bilirubin to 
the secondary sites. The value of association constant 
-i 
obtained by fluorescence enhancement method (1.72 xlO 
liters/mole) was found to be in good agreement with the 
one obtained by fluorescence quenching. (1.35 x 10 
liters/mole). This suggests the utility of the present 
method to study the interaction of bilirubin with 
albumin. The effects of pH and ionic strength on 
bilirubin-albumin interaction was studied by 
fluorescence enhancement. Binding decreased 
significantly on decreasing the pH from 9.0 to 7.0 which 
can be explained by the binding model as proposed 
earlier by Brodersen (1979). There was an increase in 
the binding upto an ionic strength of 0.15 and then 
decreased on increasing the ionic strength which is 
iii 
suggestive of the role of electrostatic interactions in 
this binding. The technique of fluorescence enhancement 
was also used to study the binding of bilirubin to 
various constituents of serum and it was found that it 
is the albumin fraction which binds bilirubin. Binding 
of bilirubin with different serum albumins was also 
studied using fluorescence enhancement and the order of 
affinity was found to be PSA > DSA > BSA > HSA > GSA. 
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INTRODUCTION 
Serum albumin constitutes a major part of the 
circulation of mammals and other higher animals and is 
regarded as a principal component of blood. It has a 
typical blood concentration of 5gm/l00ml and contributes 
about eighty percent to colloid osmotic blood pressure. 
Its important functions include the maintenance of blood 
pH (Figge et al. , 1991) and distribution of metabolites 
and drugs to various tissues of the body (Peters, 1985). 
In animals, albumin is synthesized by the liver (Peters 
and Anfinsen, 1950) and possesses a half life in 
circulation of 19 days (Waldmann, 1977). 
The most important property of albumin is its 
ability to bind a wide variety of ligands. It is also 
the principal carrier of fatty acids which are otherwise 
insoluble in circulating plasma. It also sequesters 
oxygen free radicals and inactivates various toxic 
lipophilic metabolites such as bilirubin 
(Emerson, 1989) . It also forms covalent adducts with 
pyridoxyl phosphate, cysteine, glutathione and various 
metals, such as Cu (11) , Ni(II), Hg(11) , Ag(11) and 
Au(I) . Albumin is also the reservoir of nitric oxide 
which is implicated in a number of other physiological 
processes such as neurotransmission (Stamler et al. , 
1992) . 
2 
Albumin belongs to a multigene family of proteins 
which includes «C-fetoprotein (AFP) and vitamin D-binding 
protein (VDP) also known as G complement (Gc) protein. 
AFP is considered the fetal counterpart of albumin and 
it binds to a large number of unknown ligands which are 
important in fetal development. VDP plays a role in 
calcium regulation. AFP and VDP both interact with 
class II major histocompatibility complex and this 
suggests that they have an important role in modulating 
the immune response. (Oers et al. , 1989). Albumin, 
although homologous in structure to that of AFP and VDP 
shares no immunological properties with these proteins. 
The net charge of about 185 ions/molecule at pH 
7.0 helps in the solubility of albumin. Due to the 
presence of disulfide bonds, albumin is not easily 
denatured and can withstand heat pasteurization at 
temperature of 60°C for 10 hours without deleterious 
effects (Shrake et al., 1984). 
Structural organization 
Albumin structure has been probed with diverse 
experimental methods including hydrodynamics, low angle 
X-ray scattering, fluorescence energy transfer, 
electrophoretic methods, NMR, IR, UV, Mass and Raman 
spectroscopy. Based on hydrodynamic experiments 
3 
(Hughes, 1954; Squire et al. , 1968; Wright and Thompson, 
1975) and low angle X-ray scattering (Bloomfield, 1966) ; 
serum albumin was considered as an oblate ellipsoid 
having dimensions of 140 x 41.6 A° with an axial ratio 
of 3.5. Recent studies on human serum albumin revealed 
the albumin molecule as heart shaped which can be 
approximated to an equilateral triangle with sides of 
~80A° and depth of ~30A° with an axial ratio of 
approximately 2.66 (Bos et al. , 1989; He and 
Carter, 1992) . Albumin molecule is a single polypeptide 
chain containing 17 disulfide bridges arranged in a 
series of nine loops. These loops are grouped as three 
homologous domains of three loops each by gene fusion 
event (Brown, 1977; Mc Lachlan and Walker, 1977) . In 
bovine serum albumin, the domains are known to contain 
the amino acid residues 1-190 (no.l), 191-382 (no.2) and 
383-582 (no.3) - including intradomainal connecting 
segments (Brown, 1976, 1977). These domains are further 
divided into six subdomains (Mc Lachlan and 
Walker, 1977) which were later verified by the crystal 
structure (Carter et al., 1989, Carter and He, 1990; He 
and Carter, 1992). These subdomains are predominantly 
helical and extensively cross linked by several 
disulfide bridges. Electron microscopy indicated that 
BSA was a roughly spherical molecule with a height of 
60 A° and a depth of 45 A° (Slayter, 1965) . Diffusion 
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data showed the Stokes radius of BSA to be approximately 
3 7 A° (Longsworth, 1954) . 
Primary structure and physico-chemical properties of 
albumin 
Some of the physicochemical properties of bovine serum 
albumin are summarized in Table I. Albumin molecule is 
characterized by a low content of tryptophan, glycine, 
methionine and a high content of cysteine and charged 
amino acids (Brown and Shockley, 1982; Peters, 1985). 
The primary structure is unusual as it possesses a 
single free sulfhydryl (Cys-34) and possesses no site 
for enzymatic glycosylation. This is in contrast to 
other members of albumin family such as AFP (Law and 
Dugaiczyk, 1981; Morinaga et al. , 1983), VDP (Yang et 
al., 1985; Schoentgen et al., 1986) and lamprey and frog 
albumins which are glycoproteins. 
The latest version of the amino acid sequence of 
bovine serum albumin as reported by Brown and 
Shockley, 1982 is depicted in Figure 1. The molecular 
weight of bovine serum albumin is 69,000 (Tanford, 1968) 
with a nitrogen content of 16.47%. Bovine serum albumin 
contains 582 amino acid residues and the amino acid 
composition is given in Table II. In contrast to the 
human species, bovine albumin contains two tryptophan 
residues placed in positions 134 and 212. Bovine serum 
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TABLE I 
Physicochemical Properties of Bovine Serum Albumin 
PROPERTY VALUE REFERENCE 
MOLECULAR WEIGHT 
(a) From composition 
(b) From physical data 
SEDIMENTATION COEFFICIENT 
S 2 0; W X10 1 3 
(a) monomer 
(b) dimer 
DIFFUSION COEFFICIENT 
D 2 0 , W x 10' 
PARTIAL SPECIFIC VOLUME 
66,267 
69,000 
Yo 
INTRINSIC VISCOSITY 
OVERALL DIMENSIONS AC 
4 . 5 
6 . 7 
5 . 9 
0 . 7 3 3 
0 . 0 4 1 
4 1 . 6 x 1 4 0 . 9 
REFRACTIVE INDEX 
INCREMENT 578nm x 10 3 
ISOELECTRIC POINT 
ISOIONIC POINT 
OPTICAL ABSORBANCE 
279 nm lg, liter"1 
MEAN RESIDUE ELLIPTICITY X 10" 
1.90 
4.70 
5.30 
0.667 
•3 
Brown and Shockley (1982) 
Tanford (1968) 
Squire et al. , (1968) 
Squire et al. , (1968) 
Wagner and Scharaga (1956) 
Hunter (1966) 
Mc Millan (1974) 
Wright and Thompson (1975) 
Perlmann and Longsworth (1948) 
Peters (1975) 
Foster (1960) 
Janatova et al. , (1968) 
( e ) 2 0 g nm 21.1 Noel and Hunter (1972) 
(»)->„ nm 20.1 Noel and Hunter (1972) 
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Fig. 1 : Amino acid sequence of bovine serum albumin (Brown 
and Shockley, 1982). Position of disulfide bonds are 
shown by [ Q ]. Numbers 1-9 indicate the nine double 
loops of the protein molecule. 
< 
o 
o 
N 
< 
o 
o 
z 
< 
o 
o 
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AMINO ACID SEQUENCE OF BOVINE SERUM ALBUMIN 
TABLE II 
AMINO ACID COMPOSITION OF BOVINE SERUM ALBUMIN* 
Amino Acid No. of Residues 
Aspartic acid 
Asparagine 
Threonine 
Serine 
Glutamic acid 
Glutamine 
Proline 
Glycine 
Alanine 
Valine 
1/2 Cystine 
Methionine 
Isoleucine 
Leucine 
Tyrosine 
Phenylalanine 
Lysine 
Histidine 
Tryptophan 
Arginine 
Total 
41 
13 
34 
28 
D9 
20 
28 
16 
46 
36 
35 
04 
14 
61 
19 
27 
59 
17 
02 
23 
582 
* Taken from Brown and Shockley (1982) 
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albumin also contains one single and eight pairs of 
disulfide bonds arranged in a way analogous to that of 
human albumin. The conformation of the disulfides are 
primarily gauche-gauche-gauche with torsion angles 
clustering around ± 80° (He and Carter, 1992). Majority 
of the disulfides are well protected from the reducing 
agents and are not easily accessible to the solvent 
(Katchalski et al; 1957) . Disulfide pairings are 
responsible for the typical folding topology and 
stability of albumin molecule under a variety of 
experimental conditions. 
Spectral properties of albumin suggest that the 
absorbancy peak occurs at 278.5-279 nm. The occurrence 
of ultraviolet absorption maximum at about 279 nm and a 
low value of specific extinction coefficient (6.67) are 
consistent with the low content of tryptophan in BSA 
(Peters, 1980). The fluorescence of albumin is dominated 
by its tryptophan residues with an excitation frequency 
of 295-305 nm and emission peaks at around 343 nm. Like 
all globular proteins, albumin molecule also rotates the 
plane of polarized light with a strong negative Cotton 
effect at 233 nm. Circular dichroism in the UV range 
shows minima at 209 and 222 nm (Noel and Hunter, 1972) 
and a strong maximum near 195 nm. 
As proposed by spectroscopic (Jacobsen 1972; 
Sjoholm and Ljungstedt, 1973; Chen and Lord, 1976) and 
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predictive methods (Mc Lachlan and Walker, 1977), the 
albumin structure is predominantly ^-helical. 
Approximately, 67% of HSA is helical with the remaining 
polypeptides occurring in turns and extended or flexible 
regions between subdomains (He and Carter, 1992). 
Conformational states of albumin 
Bovine serum albumin exhibits conformational 
flexibility as a function of pH. Foster classified the 
pH dependent forms as "N", for normal form, which is 
predominant at neutral pH, "B", for the basic form 
occurring at pH above 8.0; "F", for the fast moving form 
at pH values below 4.0; "E", for the expanded form at pH 
values below 3.5; and "A" for the aged form occurring 
with time at pH values greater than 8.0. The proposed 
structures of the N, F and E conformational isomers are 
illustrated in Figure 2. 
"F" form shows faster electrophoretic mobility and 
is characterized by an abrupt opening of the molecule 
(Foster, 1960). N-F transition involves the unfolding of 
domain III from the rest of the molecule (Geisow and 
Beaven, 1977; Khan, 1986) . There is an unusual increase 
in viscosity, much lower solubility and a significant 
loss in helical content (Foster, 1960; Hilak et al., 
1974) . There is a decrease in optical rotation at 
233 nm, increase in tyrosyl exposure (Herskovitz and 
10 
N form 
^W^^#-
fe form 
Fig 2 : Ribbon diagrams of serum albumin in i t s N 
form, and in i t s proposed F and E forms 
( C a r t e r and Ho, 1994) . 
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Laskowski, 1962) and increase in intrinsic viscosity 
(Tanford et al., 1967a). 
Electron microscopy revealed the F-E transition as 
expansion of the molecule with dimensions of 21 x 250A°, 
(Harrington et al. , 1956). This transition involves the 
increase in intrinsic viscosity and a rise in the axial 
ratio from about 4 to 9 and a further decrease in 
helical content. 
The N-B transition is identified by its slower 
anodic migration during electrophoresis. Structurally, 
the conformational changes occur slowly than the 
F transition and discreet steps are associated with this 
transition (Hart et al.,1986). There is a decrease in 
helical content and increase in affinity for certain 
ligands (Zurakowski and Foster, 1974). 
Ligand binding properties 
Blood plasma contains numerous transport proteins 
which have specific sites for their individual ligands 
but albumin is unique in the sense that it can bind to a 
variety of substances and hence have reversible and 
adaptable binding sites (Brodersen, 1979). Most ligands 
are bound reversibly, and typical association constants 
(Ka) range from 104 to 107 M _ 1 (See Table III) . Within 
the albumin molecule, there are distinct binding sites 
and these sites have been studied by equilibrium 
dialysis or spectroscopic methods. Although the exact 
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Table I I I 
Se l ec t ed Binding Cons tan ts for Endogenous and Exogenous 
Ligands with Serum Albumin 
L i g a n d K a l ( M ~ 1 } K a 2 ( M _ 1 ) A l b u m i n R e f e r e n c e 
ENDOGENOUS 
SUBSTANCES 
B i l i r u b i n 
Chenodeoxy-
cholate 
Cholate 
Cortisol 
Linoleate 
Palmitate 
Stearate 
5.5x10' 
2.0X10-
5.5x10' 
5.0x10" 
7.9x10 
6.2X10 
4.4x10" 
15.0X10 7 
Testosterone 2.38x10 
4 
L-tryptophan 6.3x10 
NEGATIVELY CHARGED AND 
ELECTROSTATIC NEUTRAL DRUGS 
Diazepam 4.9x10" 
Indomethacin 1.0x10 
Salicylate 2.2x10" 
Warfarin 1.5x10" 
1.0x10" 
1.6x10" 
1.5x10" 
POSITIVELY CHARGED DRUGS 
Chlorpromazine 1.9x10 
INORGANIC IONS 
.2 + 
or 
Ni 2 + 
9.0x10' 
3.0x10" 
HSAU Brodersen, (1979) 
HSA Roda et al., (1982) 
HSA 
HSAf 
HSA 
HSA 
HSA 
HSAf 
HSA 
HSA 
HSA^ 
HSAX 
HSAX 
Roda et al., (1982) 
Yates and Urguhart (1962) 
Spector and Fletcher (1978) 
Spector and Fletcher (1978) 
Spector and Fletcher (1978) 
Vermeulen and Verdonck (1968) 
Sollene et al., (1981) 
Muller and Wollert (1973) 
Hultmark et al., (1975) 
Brown and Crooks (1976) 
Brown and Crooks (1976) 
HSA Sharpies (1975) 
BSA Peters (1975) 
HSA Callan and Sunderman (1973) 
f: Serum albumin with fatty acid 
d: defatted serum albumin 
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number of discreet binding locations on albumin is 
controversial, it is assumed that there are two 
principal binding areas for small heterocyclic and 
aromatic carboxylic acids, two to three dominant long 
chain fatty acid binding sites unique and separate from 
the binding sites for small anionic compounds (at normal 
physiological concentrations) and two distinct metal 
binding sites, one involving Cys-34 and the other the 
N-terminus. Thus, with normal ligand/albumin 
concentrations, there are six dominant areas of ligand 
association to albumin. It has been proposed 
(Sjoholm et al. , 1979) that there are three binding 
sites on albumin molecule and each of these sites bind a 
variety of structurally related compounds. The best 
characterized binding sites are those of fatty acids and 
bilirubin. These ligands are physiologically important 
and are transported to the blood circulation after 
forming complex with the albumin molecule. The naturally 
occurring long chain fatty acids such as oleate, 
stearate, linoleate and palmitate are the most strongly 
bound organic ligands. The affinity of binding of the 
fatty acids for the first two to three sites on albumin 
molecule generally increases with the chain length and 
with the degree of unsaturation. The binding of the 
first two fatty acid molecules to defatted albumin 
causes a change in the dielectric properties and 
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viscosity which indicates that the ellipsoidal shape of 
the albumin molecule has become more rounded. The 
rounded, compact form of albumin is more stable against 
cleavage by proteases and denaturation by heat both of 
which have been observed with the binding of fatty acids 
(Klapper and Cann, 1964; Yu and Finlayson, 1984) . 
Esterified fatty acids also bind to albumin but with 
lower affinities. Bile salts also bind to albumin and 
the affinity decreases with the increasing number of 
hydroxyl substituents and with conjugation with glycine 
or taurine. Steroid hormones such as Cortisol and 
testosterone also bind to albumin. 
Interaction with bilirubin 
Free bilirubin is a neurotoxic substance. It is 
formed by the catabolism of hemoglobin, and circulates 
in the blood plasma bound to albumin. Bilirubin is 
conjugated in the liver with glucoronic acid and is then 
excreted in the bile. Since human neonates have an 
underdeveloped capability of conjugation, free bilirubin 
accumulates resulting in hyperbilirubenemia ultimately 
leading to kernicterus. Several drugs are known to 
displace bilirubin from albumin leading to increased 
level of bilirubin in the blood plasma which enhances 
the possibility of kernicterus and brain damage. There 
appears to be three bilirubin binding sites in albumin 
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but binding at the primary site is sufficient enough to 
prevent bilirubin from going into the central nervous 
system of neonates and causing kernicterus. 
Brodersen (1979) showed that bilirubin, although a 
lipophilic substance, is weakly soluble in apolar 
solvents because of its capability to form 
intramolecular hydrogen bonds between the carboxylate 
oxygen and pyrrole nitrogens in each dipyrrole half of 
the molecule leaving no polar groups available for 
interaction with water. Albumin causes the bilirubin 
molecule to unfold by breaking the intramolecular 
hydrogen bonds and holding it in a tight, highly twisted 
orientation in a locus protected from the surrounding 
medium (Jacobsen and Brodersen, 1983) . The binding of 
bilirubin to albumin causes a red shift in the light 
absorption maximum from 440nm to 465nm and a change in 
the chirality of the bilirubin molecule as measured by a 
strong Cotton effect (Harmatz and Blauer, 1975). The 
chiral change varies in sign among different albumin 
species which suggest that the sequence differences may 
result in twisting of the bilirubin molecule in an 
opposite sense. The binding of bilirubin to albumin is 
almost instantaneous followed by a series of relaxation 
processes over about 500 sec at 6°C as the final 
configuration is attained (Jacobsen and 
Brodersen, 1983). 
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The binding of bilirubin to albumin is affected by 
simultaneous binding of fatty acids. With a 
fatty acid/albumin ratio greater than 5 mol mol , there 
appears to be a direct competition for the bilirubin 
site, depressing bilirubin binding. Between 
0 and 2 mol mol-1, there is an enhancement for the 
bilirubin binding, seen mainly as a decrease in the rate 
of dissociation of the complex (Reed, 1977) . This 
positive cooperativity is a consequence of the change in 
the overall configuration of the albumin molecule 
produced by the binding of first few fatty acids, 
perhaps exerting an effect over some distance. 
Serum albumin has one strong and two weak binding 
sites for bilirubin (Jacobsen 1969; Reed et al., 1975). 
The weak binding sites are unimportant (Brodersen, 1979) 
in bilirubin binding and transport at physiological 
bilirubin concentrations. Bilirubin binding studies with 
tryptic and peptic fragments of BSA revealed that the 
primary binding site is located in the amino acid 
sequence 186 - 238 (Reed et al. , 1975). Lysine and 
arginine residues are known to be involved in bilirubin-
albumin interaction as they are capable of forming a 
salt bridge with the carboxylate groups of bilirubin 
(Brodersen, 1979; Peters 1985). Brodersen and coworkers 
(Brodersen, 1979; Jacobsen and Brodersen, 1983) have 
proposed a model which involves conformational changes 
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in albumin molecule as a result of bilirubin binding and 
fixation of bilirubin molecule in an asymmetric 
conformation between the two half domains of albumin. 
On the other hand it has been proposed that bilirubin 
exists in an equimolar mixture of two enantiomeric forms 
one of which prefrentially binds with albumin 
(Lightner et al. , 1986, 1988a, 1988b). In both the 
models £. -amino groups of critical lysine residues 
supposedly play a crucial role in this interaction. 
The binding of bilirubin to albumin has been 
studied earlier using fluorescence quenching method. In 
this dissertation, I have used fluorescence enhancement 
to study bilirubin-albumin interaction. Association 
constant of BSA was determined both by fluorescence 
quenching as well as by fluorescence enhancement 
methods. The value of association constant obtained by 
fluorescence enhancement method was found to be similar 
with that of fluorescence quenching. This suggests that 
fluorescence enhancement can also be used to determine 
the association constant and studying bilirubin-albumin 
interaction. 
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MATERIALS AND METHODS 
A. MATERIALS 
(i) Proteins 
Bovine serum albumin, fraction V (Batch No. 
T-818090) was purchased from Sisco Research 
Laboratories, India. Human serum albumin, fraction V 
(Lot No. 47F-9338), pig serum albumin (Lot No. 
79F-9320) , dog serum albumin, fraction V (Lot No. 
21H-9320), goat serum albumin, fraction V (Lot No. 
22H-9324), ovalbumin (Lot No. 23F-8175) 
«C-chymotrypsinogen A (Lot No. 111F-8055) and "^-globulin 
(Lot No. 89B-1390) were the products of Sigma Chemical 
Company, U.S.A. 
(ii) Media for gel chromatography 
Sephacryl S-200 (HR) with a bead diameter of 
25-75M (Lot No. 73H-0540) and blue dextran-2000 (Lot No. 
62H-0796) were obtained from Sigma Chemical Company, 
U.S.A. 
(iii) Reagents for electrophoresis 
Dimethyldichlorosilane and coomassie brilliant 
blue R-250 were purchased from Sigma Chemical Company, 
U.S.A. N,N,N',N' tetramethylethylenediamine and 
bromophenol blue were obtained from B.D.H., England and 
P.P.H., Poland respectively. Riboflavin was procured 
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from E. Merck, Germany. Acrylamide, 
N,N'-methylenebisacrylamide, ammonium persulfate, tris, 
glycerol, sucrose, glycine, acetic acid, chloroform and 
methanol were the products of Qualigens Fine Chemicals 
India. 
(iv) Other reagents 
Bilirubin (Lot No. 98F-01131) was obtained from 
Sigma Chemical Company, U.S.A. Sodium azide was 
purchased from Loba Chemie, India. Sodium chloride, 
sodium hydroxide and sodium potassium tartarate were 
obtained from Qualigens Fine Chemicals, India. 
Analytical grade samples of sodium acetate, sodium 
phosphate monobasic and dibasic, sodium hydrogen 
carbonate, sodium carbonate, sodium tungstate, sodium 
molybdate, copper sulfate, ethylenediaminetetraacetic 
acid, lithium sulfate, potassium permanganate, potassium 
dichromate, methanol, liquid bromine, orthophosphoric 
acid, hydrochloric acid, sulfuric acid and glacial 
acetic acid were used. 
(v) Miscellaneous 
Dialysis sacks of different flat widths i.e., 
25 mm (Lot No. 82H-0050) and 43 mm (Lot No. 92H-0291) 
were purchased from Sigma Chemical Company, U.S.A. 
Millipore filters of pore size 0.45;u and 13 mm diameter 
were the products of Millipore Product Division, 
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Bedford, U.S.A. Whatman filter paper, No. 1 (12.5 cm 
diameter) was obtained from Whatman Ltd., England. Solid 
glass beads (5 mm diameter) were from Kimble Resistant 
Glass, U.S.A. Buffer tablets of pH 4.0, 7.0 and 9.2 were 
obtained from Qualigens Fine Chemicals, India. 
All glass distilled water was used throughout this 
study. 
B. METHODS 
(i) pH measurements 
pH measurements were made on an Elico pH meter, 
model L1-10T equipped with a combined glass electrode, 
CL-51. Before each measurement, pH meter was calibrated 
with standard buffers of pH 4.0, 7.0 and 9.2 in the 
acidic, neutral and alkaline pH ranges respectively. 
(ii) Optical measurements 
Optical measurements in the ultraviolet and 
visible regions were carried out on Shimadzu double beam 
spectrophotometer, model UV 150-02 using matched silica 
cuvettes of 1 cm pathlength. 
Fluorescence measurements were made on Shimadzu 
spectrofluorophotometer, model RF-540 equipped with a 
data recorder, model DR-3 using a single quartz cuvette 
of 1 cm pathlength. Other accessories include a water 
jacketed cell holder, a mini magnetic stirrer, 
(Helima cuv-o-stir, model 333) and a constant 
temperature water circulator, model TB-85. 
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(iii) Determination of protein concentration 
Following methods were used to determine the 
protein concentration. 
(a) Method of Lowry et al., (1951): This method 
involves the use of two reagents, namely, Folin-phenol 
reagent and copper reagent. 
Preparation of Folin-phenol reagent: Folin-phenol 
reagent was prepared according to the method of Folin 
and Ciocalteau (1927). To a two liter flat bottom flask, 
wrapped with a black paper, were added 100 gms of sodium 
tungstate, 25 gms of sodium molybdate, 50 ml of 85% 
orthophosphoric acid, 100 ml of 11.4 N hydrochloric acid 
and 700 ml of water. The mixture was refluxed for about 
10 hours. Afterwards, 150 gm of lithium sulfate, 50 ml 
of water and few drops of liquid bromine were added. 
Finally, the mixture was heated without condenser for 
about half an hour to remove excess of bromine. After 
cooling, the total volume was made upto 1 liter with 
water. This stock solution was filtered and stored in an 
amber colored bottle. It was diluted four times with 
water before use. 
Preparation of copper reagent: The stock solutions of 
4%(w/v) sodium carbonate, 4%(w/v) sodium potassium 
tartarate and 2% (w/v) copper sulfate were prepared. 
These solutions were mixed in the ratio of 100:1:1 
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respectively. The reagent was prepared fresh and 
filtered before use. 
Method: Different volumes of stock protein solution 
ranging from 0.1 to 1.0 ml were taken in different test 
tubes and the final volume was made upto 1 ml either 
with water or buffer. To this solution was added 5 ml of 
freshly prepared copper reagent. The solution was mixed 
thoroughly and kept at room temperature for 10 minutes. 
Then, 1 ml of working Folin-phenol reagent was added to 
each tube. The contents were mixed well and kept at room 
temperature for 30 minutes. The color intensity was read 
at 700 nm against a blank which was prepared in the same 
way except that water or buffer was used in place of 
protein. 
(b) Spectrophotometrie method: The absorbance of protein 
solution was measured at 279 nm against an appropriate 
blank. The concentration of protein was determined by 
using specific extinction coefficient (E -, ) value of 
5.31 (Edward et al. , 1969) and 6.67 (Janatova et al. , 
1968) for HSA and BSA respectively. Scattering 
corrections, when needed, were made by extrapolating the 
absorbance values in the wavelength region of 360-330 nm 
to the desired wavelength and subtracting it from the 
absorbance of protein. 
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(iv) Polyacrylamide gel electrophoresis 
Polyacrylamide gel electrophoresis was carried out 
in tris-glycine buffer, pH 8.2 (1=0.02) essentially 
according to the method of Davis (1964). 
The gel plates (10.8 x 10.8 cm) were, washed with 
detergent, chromic acid and finally with water. The 
plates were dried, siliconised and any sticky material 
was removed by cotton. Three plastic spacers were placed 
along the sides and the bottom of the glass plates. The 
plates were mounted in vertical upright position with 
the help of clamps. Two clamps were used to hold the two 
plates along the sides. The bottom and the sides of the 
plates were sealed with 1% agarose solution. The space 
between glass plates was filled with small pore solution 
containing 7% (w/v) acrylamide, 0.18% (w/v) 
N,N'-methylenebisacrylamide, 0.03% (v/v) , N,N,N',N'-
tetramethylethylenediamine (TEMED) and 0.07% (w/v) 
ammonium persulfate. A comb was placed at notch on the 
top of the glass plates. It was left for polymerization 
at room temperature for about 3 0 minutes. Then the comb 
was removed and the wells were rinsed with sample 
buffer. 
For sample preparation, 0.3 mg of protein was 
taken in 1 ml of electrophoresis buffer containing 
20% (w/v) sucrose and 0.01% (w/v) bromophenol blue. 
The two clamps, the bottom bracket and the plastic 
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spacer at the bottom were then removed. Buffer was 
removed from the wells by inverting the glass plates and 
soaking it with filter paper strips. The lower tank of 
the Broviga mini vertical slab gel electrophoresis 
apparatus was filled with electrophoresis buffer. The 
glass plates were held in place in the electrophoresis 
unit with the help of two clamps. Extreme care was taken 
to avoid the formation of bubbles at the bottom. About 
15 ;ul of the sample solution containing nearly 4.5 p.g 
protein was loaded in each well with the help of a 
micropipette. The empty space of the wells was filled 
with the electrophoresis buffer. After filling the upper 
chamber with electrophoresis buffer, an anodic current 
of 2-3 mA per well was passed. Electrophoresis was 
carried out till the bromophenol blue front had migrated 
to nearly three-fourth of the total length of the gel. 
After electrophoresis, gel was taken out from the plates 
by passing a jet of water in between the gel and the 
glass plates with the help of a syringe. The gel was 
stained with coomassie brilliant blue (0.1% w/v 
coomassie brilliant blue R-250 solution, prepared in 
42% (v/v) methanol and 17% (v/v) acetic acid, for 
overnight. Destaining was performed first with 30% (v/v) 
methanol and 10% (v/v) acetic acid solution and then 
with 7% (v/v) acetic acid until the background was 
clear. The relative mobility was obtained by dividing 
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the distance travelled by the protein band with that of 
the tracking dye. 
(v) Gel filtration 
Gel filtration was performed on a prepacked 
Sephacryl S-200(HR) column (99 x 2.4 cm) equilibrated 
with 0.06 M sodium phosphate buffer, pH 7.0 containing 
0.02% sodium azide. For sample application, the 
operating buffer above the column bed was first drained 
off and the sample (500 mg of BSA/3 ml) was applied on 
the column. The stop cock was then opened slowly and the 
sample was allowed to pass down the upper surface of the 
gel. When all the protein sample had passed into the 
gel, buffer was applied and finally connected to a 
reservoir. The elution was performed with a constant 
flow rate of 32 ml/hr. Fractions of 5 ml were collected 
and monitored for protein by the method of 
Lowry et al. , (1951). Before passing protein, the 
homogeneity of the column was established by passing 
2 ml of 1.5% (w/v) blue dextran solution through the 
column. The elution volume of blue dextran yielded the 
void volume (Vo) of the column. 
(vi) Determination of molecular weight of protein 
The Sephacryl S-200 (HR) column (99 x 2.4 cm) was 
calibrated with marker proteins of known molecular 
weights such as human serum albumin dimer (135,000), 
human serum albumin monomer (67,000), if-globulin 
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(150,000), ovalbumin (45,000) and C-chymotrypsinogen 
(25,000). Ten milligrams of each marker protein in 2 ml 
of buffer was applied on the column and eluted with a 
flow rate of 36 ml/hr. Fractions of 2 ml were collected 
and monitored by the method of Lowry et al. , (1951) by 
taking 0.4 ml from each fraction. A graph was plotted 
between Ve/Vo Vs log M to determine the molecular weight 
of unknown protein. 
(vii) Fractionation of the plasma proteins 
Plasma proteins were fractionated on Sephacryl 
S-200(HR) column. Before fractionation, plasma was 
collected from the human blood obtained from the Blood 
Bank of J.N. Medical College, after centrifugation at 
4000 rpm for 20 minutes and stored at 4°C. The plasma 
was diluted hundred times with 0.15 M NaCl and the 
protein concentration was determined by the method of 
Lowry et al. , (1951). Two milliliters of plasma 
containing nearly 145 mg protein was applied on the 
column equilibrated with 0.06 M sodium phosphate buffer, 
pH 7.0 containing 0.02% sodium azide. The elution was 
performed with a flow rate of 36 ml/hr and fractions of 
2 ml were collected. They were monitored for protein by 
taking o.l ml from each fraction by the method of 
Lowry et al., (1951). 
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(viii) Bilirubin binding studies 
The interaction of bilirubin with albumin was 
studied fluorometrically using both fluorescence 
quenching and fluorescence enhancement methods. 
Experiments were performed in dim light to avoid 
photodecomposition and photoisomerization of bilirubin. 
Tris-HCC buffer (0.1M), pH 8.0 was used in all bilirubin 
binding experiments unless otherwise stated. 
(a) Preparation of bilirubin solution : Bilirubin 
solution was prepared by dissolving few crystals of 
bilirubin in 1 ml of 1 M sodium carbonate solution 
containing ImM EDTA and the desired volume was made 
upto 10 ml with water. The solution was filtered and 
stored in dark. The concentration of bilirubin was 
determined spectrophotometrically by taking the 
absorbance of the bilirubin solution at 440 nm using 
molar extinction coefficient of 47,500 (Jacobsen and 
Wennberg, 1974) after diluting it 50 times with the 
buffer. The solution was prepared fresh and used within 
two hours. 
(b) Fluorescence quenching method: The titration was 
performed in a discontinuous manner by taking a fixed 
amount of protein (1 ml) in a series of tubes and adding 
to it increasing aliquots of stock bilirubin solution to 
obtain a molar ratio in the range of 0.05 to 5.0. The 
final volume in each tube was made upto 5 ml with 
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buffer. The incubation mixture was mixed thoroughly and 
it was allowed to stand at room temperature for 
5 minutes. The fluorescence spectra were recorded in the 
wavelength range of 300-400 nm by exciting the protein 
at 282 nm using a slit width of 5 nm. The data were 
analysed according to the method of Levine (1977). 
The fluorescence intensities at 340 nm, emission 
maxima of protein, in the presence of bilirubin were 
transformed into relative fluorescence by taking the 
fluorescence of the bilirubin free protein solution to 
be 100. A graph was plotted between relative 
fluorescence and bilirubin/albumin molar ratio. A least 
squares analysis of the initial linear points of the 
graph was used to determine the maximal quench (m) from 
the following relationship : 
F = Fo - mR (1) 
where F is the fluorescence at bilirubin/albumin ratio 
(R) and Fo is the fluorescence of protein in the absence 
of bilirubin. Therefore, for the first binding site 
(R = 1.0), the maximal quench (ir^ ) was calculated by 
follwing equation : 
F 1 Fo - m1 (2) 
m-L Fo - F± (3) 
where F-, is the fluorescence observed when one molecule 
of bilirubin is bound to each molecule of albumin using 
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points deviating from straight line. The fractional 
quench, Q was determined at each bilirubin/albumin molar 
ratio with the help of following relationship : 
Fo - F Fo - F 
Q = = ( 4 ) 
m1 Fo - F-L 
F r a c t i o n a l q u e n c h , Q i s l i n e a r l y r e l a t e d t o b i n d i n g . 
Thus : 
[ B i l - A l b ] 
Q = ( 5 ) 
[ A l b ] T 
where [ B i l - A l b ] i s t h e c o n c e n t r a t i o n of a lbumin bound 
b i l i r u b i n and [ A l b ] T i s t h e t o t a l a l b u m i n c o n c e n t r a t i o n . 
Then t h e unbound b i l i r u b i n , [B i l ] and unbound a lbumin 
[Alb] a r e : 
[ B i l ] = [ B i l ] T - [B i l -A lb ] (6) 
[ B i l ] = [ B i l ] T - Q [ A l b ] T (7) 
and [Alb] = [ A l b ] T - [B i l -A lb ] (8) 
o r [Alb] = [ A l b ] T - Q [Alb] T (9) 
= (1-Q) [ A l b ] T (10) 
U s i n g t h e a s s o c i a t i o n c o n s t a n t , Ka 
[ B i l - A l b ] 
Ka = ( H i 
[Alb] [B i l ] 
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Substituting with equations (5-7) and (10) 
Q [ A l b ] T 
Ka = (12) 
(1-Q) [ A l b ] T ( [ B i l ] T - Q [ A l b ] T ) 
or 
Q 
Ka = (13) 
(1-Q) ( [Bil]
 T/[Alb] T - Q) [Alb]T) 
Since ratio (R) is given by 
[Bil]T 
R = (14) 
[Alb]T 
Q 
Then Ka = (15) 
(1-Q) (R-Q) [Alb]T 
The data were analysed for the determination of 
association constant and binding capacity, by utilising 
the Scatchard equation (Scatchard, 1949). The final 
transformed Scatchard equation is 
[Bil-Alb] Ka [Bil-Alb] 
nKa - = (16) 
[Alb]T [Bil] [Alb]T 
Q Q 
o r nka - K a Q = = (17! 
[B i l ] [R-Q] [ A l b ] T 
where n i s t h e b i n d i n g c a p a c i t y . 
The . l e a s t s q u a r e s a n a l y s i s of t h e p l o t be tween 
Q a n d Q/ [ B i l ] y i e l d e d t h e a s s o c i a t i o n c o n s t a n t a s 
o b t a i n e d from t h e v a l u e of s l o p e i . e . , -Ka and t h e 
b i n d i n g c a p a c i t y , n ( i n t e r c e p t on X - a x i s ) . 
31 
(c) Fluorescence enhancement method The titration 
was performed in an exactly identical manner as that for 
fluorescence quench method except that the fluorescence 
emission spectra were recorded in the wavelength range 
of 500-600 nm after excitation at 487 nm using a slit 
width of 5 nm. The data were analysed in the following 
way. 
The fluorescence intensity at emission maximum 
i.e., 528 nm obtained at each bilirubin/albumin molar 
ratio was corrected by subtracting the fluorescence 
intensity value obtained in absence of bilirubin from 
the fluorescence values obtained at each molar ratio. 
The fluorescence intensity was plotted against 
bilirubin/albumin molar ratio. The initial linear points 
were fitted into a straight line equation with the help 
of least squares analysis. The modified version of 
equation (3) as described by Levine (1977) yielded the 
value of e-, (maximal enhancement at bilirubin/albumin 
molar ratio 1.0) 
e± = Fx - F0 (18) 
where F, is fluorescence intensity at bilirubin/albumin 
ratio 1.0 and F is fluorescence intensity at zero 
bilirubin concentration. For each fluorescence value, F, 
32 
the fractional enhancement, E was calculated by the 
following equation : 
F - Fo 
E = (19) 
e 
Since enhancement is 
binding, therefore 
[Bil-Alb] 
E = (21) 
[Alb]
 T 
where [Bil-Alb] is the concentration of bilirubin bound 
albumin and [Alb]T is the total albumin concentration. 
Finally, the unbound and bound bilirubin and 
albumin concentrations were determined by using the 
simple modified version of equations 6-14. The final 
form is as follows : 
E 
Ka = (22) 
[(1-E) (R-E) [Alb]T 
The t r a n s f o r m a t i o n of above equa t ion i n t o Scatchard 
equation gave the following re l a t ionsh ip : 
E E 
nKa - KaE = = (23) 
[Bil] (R-E) [Alb]T 
The value of association constant, Ka was determined 
from a straight line plot between E and E/ [Bil] . The 
F - Fo 
(20) 
Fl " Fo 
linearly related to the extent of 
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slope of the plot is -Ka (association constant) and 
intercept on X-axis is binding capacity, n. 
(d) Effect of pH: The effect of pH on bilirubin-albumin 
interaction was studied by the technique of fluorescence 
enhancement. The BSA monomer was dialysed extensively 
against 0.15 M NaCl solution. Various buffers of 
different pH and same ionic strength (0.10) i.e., 0.15 M 
NaCl-NaOH mixture, pH 9.3, 0.06 M carbonate-bicarbonate 
buffer, pH 10.0, 0.18 M and 0.12 M Tris-HCl buffer pH 
8.2, 8.0, 7.6, 7.3, 0.055 M sodium phosphate buffer, pH 
7.0, 0.1 M sodium acetate buffer, pH 5.6, 4.6, 4.0, 3.6, 
0.7 M Glycine-HCl buffer, pH 2.7, 2.3 were prepared. To 
0.3 ml of BSA solution (cone. = 2 . 5 juM) was added 8.7 ml 
of buffer of desired pH and 1.0 ml of the stock 
bilirubin solution to get the bilirubin/albumin ratio as 
one. The contents were mixed thoroughly and allowed to 
stand for 5 minutes. Fluorescence emission spectra were 
recorded in the wavelength range of 500-600 nm by 
excitation at 487 nm. 
(e) Effect of ionic strength: Fluorescence enhancement 
method was also used to study the effect of ionic 
strength on bilirubin-albumin interaction. Stock 0.005 M 
sodium phosphate buffer, pH 8.0 was used in various 
experiments and the desired ionic strength was made by 
adding requisite amounts of NaCl. BSA was dialysed 
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against the stock buffer. To 0.25 ml of BSA solution 
(cone. =2.75 pM) was added 3.75 ml of buffer of desired 
ionic strength and 1.0 ml of stock bilirubin solution in 
order to obtain the molar ratio of bilirubin to albumin 
as one. The contents were mixed well and left for 
5 minutes. Fluorescence emission spectra were recorded 
in the wavelength range of 500-600 nm by excitation at 
4 87 nm. 
(f) Bilirubin binding to different serum albumins: The 
interaction of bilirubin with serum albumins obtained 
from different species such as human, goat, dog and pig 
was studied in 0.055 M sodium phosphate buffer, pH 8.0 
at 28°C using fluorescence enhancement technique in the 
same way as described above. 
ando/sk vidamttm 
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RESULTS AND DISCUSSION 
(i) Isolation of serum albumin monomer 
The commercial preparation of BSA contains higher 
aggregates, dimer and monomer. Since all the studies 
were performed with serum albumin monomer, it was 
isolated by gel filtration of commercial preparation on 
Sephacryl S-200 (HR) column as described in the 
experimental section. Figure 3 A shows the elution 
profile of commercial BSA on Sephacryl S-200 (HR) 
column. Two distinct peaks were obtained having Ve/Vo of 
1.1 and 1.3 respectively. Peak I corresponded to a dimer 
whereas peak II contained the monomer. Fractions under 
peak II, marked by a solid bar, were pooled together and 
stored at 4°C. The purity of the monomer was checked 
both by gel filtration as well as by polyacrylamide gel 
electrophoresis. Rechromatography of peak II on the same 
column yielded a single symmetrical peak with Ve/Vo of 
1.3 as shown in Figure 3 B, indicating size homogeneity 
of the preparation. The isolated monomer preparation 
travelled as a single major band with relative mobility 
of 0.72 on polyacrylamide gel electrophoresis as 
compared to the two bands, namely, I and II observed 
with commercial BSA preparation with relative mobilities 
of 0.52 and 0.72 respectively (See insets of Fig. 3 A 
and B) . Presence of a single band in isolated monomer 
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Fig. 3 : Elution profile of commercial BSA (A) on a Sephacryl 
S-200 (HR) column (99x2.4 cm ). The column was 
equilibrated with 0.06 M sodium phosphate buffer, pH 
7.0 containing 0.02% sodium azide. Nearly 500 mg of 
protein in 3 ml of buffer was applied on the column. 
The protein was eluted at a flow rate of 32 ml/hr 
and fractions of 5 ml were collected. The 
fractions were monitored for protein by the method of 
Lowry e_t a_l_. , (1951). Fractions under peak II were 
pooled and rechromatographed on the same column under 
similar experimental conditions (B). Insets show the 
electrophoretic patterns of commercial BSA as well 
as BSA monomer on 7% polyacrylamide gel at pH 8.2. 
o b 
1 
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with an electrophoretic mobility of 0.72 corresponding 
to band II (monomer) obtained with commercial BSA 
preparation was indicative of charge homogeneity of the 
isolated monomer preparation. This preparation was used 
throughout these studies. 
(ii) Bilirubin binding studies 
(a) Fluorescence quenching 
Bovine serum albumin gave an emission spectrum in 
the wavelength range of 300-400 nm with emission maxima 
at 340 nm. Addition of bilirubin caused quenching in its 
emission spectrum. This quenching was indicative of the 
binding of bilirubin to albumin and has also been 
observed earlier (Berde et al. , 1979; Brodersen, 1979; 
Tayyab & Qasim, 1987). There was a concomitant increase 
in fluorescence quenching on increasing bilirubin 
concentration upto a bilirubin/albumin molar ratio of 
4.0. Fluorescence emission spectra of BSA obtained at 
different bilirubin concentrations are shown in 
Figure 4. The fluorescence data were analysed according 
to the method of Levine (1977) as described in the 
experimental section. Figure 5 A shows a decrease in 
fluorescence intensity on increasing molar ratio between 
bilirubin and albumin. Fluorescence data obtained upto 
bilirubin/albumin molar ratio 1.0 were transformed into 
Scatchard equation as described by Levine (1977) and 
Scatchard plot between [Bil]
 bouncj/[Bil ] f r e e Vs 
in 
z 
UJ 
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Fig. 4 : Fluorescence emission spectra of BSA obtained at 
different bilirubin/albumin molar ratios after 
exciting the protein at 282nm. Bilirubin/albumin 
to 
molar ratios were (from to^ > bottom): 0.0 (control), 
0.10, 0.15, 0.20, 0.25, 0.30, 0.34, 0.39, 0.44, 0.54, 
0.64, 0.69, 0.74, 0.79, 0.84, 0.93, 1.87, 2.33, 2.80 
and 3.75. The titration of BSA was performed in 
Tris-HCl buffer, pH 8.0, 1=0.06 with increasing 
concentration of bilirubin. The protein concentration 
was 2.5 JJM. 
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Fig. 5A : Plot showing relative fluorescence versus bilirubin/ 
albumin molar ratio. BSA concentration was 2.5 /iM. 
Data was taken from Figure 4. 
B : Scatchard plot for the interaction of bilirubin 
with albumin at pH 8.0;,1=0.06. Fluorescence data of 
Figure 5A were transformed into scatchard plot using 
— — ~ as described equation nKa-KaQ = — 
[Bil] 
in Materials and Methods. 
[R-Q][Mb]T 
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[Bil]bound is shown in Figure 5 B. The association 
constant, Ka as obtained from the slope of the Scatchard 
plot was found to be 1.35 x 107 liters/mole for the 
interaction of bilirubin to BSA. This value was found to 
be in agreement with the value (1.8x10 liters/mole) 
reported earlier (Mir et al. , 1992). 
(b) Fluorescence enhancement 
In addition to the phenomena of fluorescence 
quenching observed in case of BSA upon addition of 
bilirubin, there was an appearance of fluorescence at 
528 nm which increased on increasing bilirubin 
concentration. This can be accounted due to the 
formation of bilirubin-albumin complex which gave 
fluorescence. Using emission wavelength of 528 nm, its 
excitation wavelength was found to be 487 nm. In 
subsequent experiments, complex between bilirubin and 
albumin was allowed to be formed and then excited at 
487 nm. Emission spectra were recorded upto a 
bilirubin/albumin molar ratio of 5.0 and are shown in 
Figure 6. As can be seen from the figure, fluorescence 
of bilirubin-albumin complex increased linearly upto a 
bilirubin/albumin molar ratio of 1.0 and then it sloped 
off. This has clearly been shown in Figure 7 in which 
fluorescence intensity at 528 nm was plotted against 
bilirubin/albumin molar ratio after correcting it with 
the fluorescence obtained at zero bilirubin 
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Fig. 6 : Fluorescence emission spectra of bilirubin^ 
albumin complex in presence of different 
concentrations of bilirubin obtained in 
tris-HCl buffer, pH 8.0, 1=0.06 after 
exciting it at 487 nm. The molar ratio 
of bilirubin to albumin were (from top 
to bottom): 5.00, 4.50, 4.00, 3.60, 
3.10, 2.90, 2.00, 1.80, 1.60, 1.40, 
1.20,1.00, 0.87, 0.68, 0.56, 0.50, 0.31, 
0.25, 0.19, 0.12, 0.06 and 0.0. Albumin 
concentration was 1 /iM. 
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Plot showing fluorescence intensity of bilirubin-
albumin complex at 528 nm versus bilirubin/albumin 
molar ratio. The concentration of BSA was 1 uM. 
Data were taken from Figure 6. 
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concentration. In these experiments, albumin 
concentration was fixed and kept at 1 pM. However, if 
the albumin concentration was increased and titrated 
with increasing concentrations of bilirubin, 
fluorescence of bilirubin-albumin complex at 528 nm 
changed in a different manner. Results obtained with 
different fixed concentrations of albumin i.e., 2.5 pM, 
10 jaM and 20 jaM are shown in Figures 8-10. Titration of 
albumin at a concentration of 2.5 pM with bilirubin upto 
a molar ratio of 4.0 resulted in similar effect on 
fluorescence as was obtained with 1 yuM albumin 
concentration (see Figures 7 & 8). On the other hand, if 
higher concentration of albumin such as 10 pM and 20 pM 
were used, fluorescence at 528 nm increased reaching to 
a maximum value around bilirubin/albumin molar ratio, 
1.0 and then decreased significantly on increasing 
bilirubin/albumin molar ratio upto 5.0. This unusual 
behavior can be explained on the basis of structural 
perturbations in albumin molecule brought about by the 
binding of bilirubin molecules to secondary sites. 
Therefore, in subsequent bilirubin binding experiments, 
2.5 pM albumin concentration was used. The data of 
Figure 8 were transformed into Scatchard plot as shown 
in Figure 11 and the value of association constant was 
found to be 1.72x10 liters/mole which was almost 
similar to the value of association constant (1.35x10 
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Fig. 8 : Plot showing fluorescence intensity of 
bilirubin-albumin complex at 528 nm versus 
bilirubin/albumin molar ratio.The concentration 
of BSA was 2.5 uM. 
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Pig. Plot showing fluorescence intensity of bilirubin-
albumin complex at 528 nm versus bilirubin/albumin 
molar ratio. The concentration of BSA was 10 ,uM. 
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Fig. 10 : Plot showing fluorescence intensity of bilirubin-albumin 
complex at 528 nm versus bilirubin/albumin molar ratio. 
The concentration of BSA was 20 ^ uM. 
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Fig. 11 : Scatchard plot for the interaction of 
bilirubin with albumin at pH 8.0-/ 
1=0.06. Data of Figure 8 were transformed 
according to equation: 
E E nKa-KaE = • 
[Bil] (R-E)[Alb]T 
as described in Materials and Methods. 
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liters/mole) obtained by fluorescence quenching method. 
This suggests that fluorescence enhancement method can 
be used fairly successfully for the determination of 
association constant. 
(iii) Effect of pH on bilirubin-albumin interaction 
Bilirubin-albumin interaction was studied at 
different pH values viz. 10.0, 9.3, 8.2, 8.0, 7.6, 
7.3, 7.0, 5.6, 4.6, 4.0, 3.6, 2.7 and 2.3 and spectra 
obtained are shown in Figure 12 A. Relative fluorescence 
obtained at 528 nm at each pH value was plotted against 
pH and the plot is shown in Figure 12 B. As can be seen 
clearly from Figure 12 B, fluorescence of the bilirubin-
albumin complex decreased on decreasing the pH from 10 
to 2.3. The decrease in bilirubin binding was more 
significant in the range of pH 7.0 to 9.0. It should be 
noted that in this pH range (7.0 - 9.0) , albumin 
molecule undergoes N-B transition. In an earlier study, 
it has been shown that light absorption spectrum of 
bilirubin albumin complex shifts in this pH range 
without any change of binding affinity (Wennberg and 
Cowger, 1973). Therefore, the decrease in fluorescence 
on decreasing the pH from 9.0 to 7.0 can be explained by 
a binding model as proposed by Brodersen (1979) in which 
each chromophore is bound to one half domain and the 
change of pH may cause the half domains to rotate 
relative to each other. In the absence of the values of 
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12A : Fluorescence emission spectra of bilirubin-albumin 
complex obtained at different pH values, viz. (from 
top to bottom): 10.0, 9.3, 8.2, 8.0, 7.6, 7.3, 7.0, 
5.6, 4.6, 4.0,3.6,2.7and 2.3. Various buffers of 
different pH and same ionic strength (0.10) were 
used as described in Materials and Methods. 
B : Effect of pH on the binding of bilirubin to BSA. 
Relative fluorescence values as calculated from the 
data of Figure 12A were plotted against pH. 
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binding constant at different pH, it is difficult to 
preclude the possibility of the decrease in affinity of 
albumin to bind bilirubin on decreasing pH. 
(iv) Effect of ionic strength on bilirubin-albumin 
interaction 
Bilirubin binding to BSA was studied at different 
ionic strengths viz. 0.01, 0.05, 0.15, 0.5 and 1.0 and 
the fluorescence spectra are shown in Figure 13 A. 
Relative fluorescence at 528 nm was plotted against 
ionic strength and the plot is shown in Figure 13 B. As 
can be seen from Figure 13 B, bilirubin-albumin complex 
formation increased on increasing the ionic strength to 
0.15 and then decreased. Decrease in bilirubin binding 
to BSA on increasing the ionic strength was suggestive 
of the role of electrostatic interactions in complex 
formation involving negatively charged carboxyl groups 
of bilirubin and some positively charged amino acid 
residues of albumin. These results are similar to those 
observed earlier by Jacobsen (1977). 
(v) Bilirubin binding to different plasma protein 
fractions 
Figure 14 shows a chromatographic profile of human 
plasma on Sephacryl S-200 (HR) column. Three major-
peaks, namely, P1# P2, and P3 with percent yield of 14%, 
32% and 54% respectively were obtained. Fractions under 
the peaks, marked by a solid bar were pooled and stored 
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13A : Fluorescence emission spectra of bilirubin-albumin 
complex obtained at different ionic strengths (from 
top to bottom) viz. 0.15, 0.05, 0.01, 0.5andl.O. In 
these experiments 0.005 M sodium phosphate buffer, 
pH 8.0 was used and desired ionic strength was 
adjusted by adding requisite amount of sodium 
chloride. 
B : Effect of ionic strength on the binding of bilirubin 
to BSA. Relative fluorescence values as calculated 
from the data of Figure 13A were plotted against 
ionic strength. 
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ELUTION VOLUME (ml) 
Gel chromatographic profile of human plasma on 
Sephacryl S-200 (HR) column (99x2.4 cm ) equilibrated 
with 0.06 M sodium phosphate buffer, pH 7.0 
containing 0.02% sodium azide. Nearly 145 mg of 
protein in 2.0 ml of buffer was applied on the 
column. The protein was eluted at a flow rate of 
36 ml/hr. Fractions of 2 ml were collected and 
monitored for protein by the method of Lowry et al. , 
(1951). 
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at 4°C. Their molecular weights were determined on a 
calibrated Sephacryl S-200 (HR) column. Elution profiles 
of various marker proteins, namely, Tf-globulin, human 
serum albumin, ovalbumin and oc-chymotrypsinogen 
alongwith the elution profile of blue dextran are shown 
in Figure 15. Values of elution volume, Ve, obtained 
with different plasma proteins as well as marker 
proteins are given in Table IV and were used to 
determine Ve/Vo (see Table IV) . The calibration curve 
between Ve/Vo and log M is shown in Figure 16. Using 
this calibration curve, molecular weights of major 
fractions of plasma proteins were determined and found 
to be 251188.64, 125,900 and 63,100 for peaks P1# P2 and 
Po respectively. The binding of bilirubin to these 
fractions was studied using fluorescence enhancement 
technique. Figure 17 A & B shows the fluorescence 
spectra of plasma fractions P-^  and P2 in presence of 
bilirubin. Fluorescence spectra of proteins in absence 
of bilirubin are also included. As is clear from Figure 
17, fractions P^ and P2 did not bind bilirubin. Large 
fluorescence observed in these fractions at 528 nm was 
suggestive of the presence of a fluorophore in these 
fractions which gave fluorescence at 528 nm. Addition of 
bilirubin did not lead to any significant enhancement in 
fluorescence. On the other hand, plasma fraction P3 
showed significant binding as addition of bilirubin to 
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Fig. 15 : Elution profiles of marker proteins and blue dextran 
on a Sephacryl S-200 (HR) column (99x2.4 cm ) 
equilibrated with 0.06 M sodium phosphate buffer, 
pH 7.0. About 6 mg of blue dextran-2000 and 10 mg of 
each marker protein dissolved in 2 ml of the same 
buffer was applied on the column. The column was run 
at 36 ml/hr. Fractions of 2 ml were collected and 
monitored at 625 nm for blue dextran and at 700 nm 
for protein by the method of Lowry e_t a_l. , (1951). 
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TABLE IV 
Gel filtration results of various marker proteins and plasma proteins on 
Sephacryl S-200 (HR) column. 
S. Proteins Mol. wt.(M) Log M Elution Volume (Ve) Ve/Vo 
No. (kd)* (ml) 
1. V-Globulin 150** 5.18 192 1.21 
2. HSA (dimer) 135 5.13 190 1.19 
(monomer) 67 4.83 217 1.36 
3. Ovalbumin 45 4.65 230 1.45 
4. ^ -chymotrypsinogen 25 4.40 268 1.69 
5. Peak I - - 166 1.04 
6. Peak II - 196 1.23 
7. Peak III - - 228 1.43 
Taken from Andrews (1970). 
Putnam, F.W. (ed.) (1975): The Plasma Protein 2nd ed. Vol.1, Academic 
Press, Inc. New York. 
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Fig. 16 : Plot of Ve/Vo versus log M. The different marker 
proteins are : 1. "C-chymotrypsinogen, 2. Ovalbumin, 
3. HSA monomer 4. HSA dimer and 5. TT-globulin. 
Positions of the different peaks (P, , P~ 4 P.,) as 
obtained in Figure 14 are shown by arrows. 
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Fig. 17 : Fluorescence emission spectra of different 
peaks namely P, (A) and P~(B) obtained on 
fractionation of human plasma by gel 
filtration in the absence and presence of 
bilirubin. The spectra from top-to bottom 
represent protein P, / or P- in the presence 
of bilirubin at a molar ratio 1:1 (1), 
protein in buffer (2), bilirubin in buffer 
(3) and buffer (4). The experiment was 
performed in tris-HCl buffer, pH 8.0. 1=0.06 
using 2.5 pM protein concentration. 
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this fraction lead to significant enhancement in 
fluorescence at 528 nm (see Figure 18 A) . This is more 
clearly shown in Figure 19 where difference in 
fluorescence of protein in presence and absence of 
bilirubin was plotted. Taking into consideration the 
molecular weight of this fraction i.e. 63,100 it seems 
that it represents albumin which is known to bind 
bilirubin. Thus, out of the three major fractions 
obtained from human plasma by Sephacryl S-200 (HR) gel 
chromatography, only fraction P-^  (representing albumin) 
was able to show bilirubin binding. From the data of 
Figure 18 A, an association constant value was 
determined to be 1.7xl07 liters/mole (see Figure 18 B) 
which was similar to the value obtained with bovine 
serum albumin. 
(vi) Bilirubin binding to different serum albumins 
Interaction of bilirubin to serum albumins 
obtained from different species, namely, pig, dog, human 
and goat was studied at pH 8.0 (1 = 0.15) and at 28°C by 
fluorescence enhancement technique. The fluorescence 
spectra obtained with these albumin preparations at 
different bilirubin concentrations are shown in 
Figure 20 A-D. The data of Figure 20 were transformed 
into Scatchard plots as shown in Figure 21 and the 
values of association constants are given in Table V. 
Value of association constant of bovine serum albumin 
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Fig. 18A : Fluorescence emission spectra of Peak 3 namely P3 
at different bilirubin/albumin molar ratios. The 
spectra from top to bottom were obtained at 
bilirubin/albumin molar ratios of 1.00, 0.91, 
0.81, 0.61, 0.51, 0.40, 0.30, 0.20, O.lOand 0.0. 
The titration was performed in tris-HCl buffer, 
pH 8.0, 1=0.06 using 2.5 ^ M protein concentration. 
B : Plot showing the fluorescence intensity at 528 nm 
obtained with peak 3 (P3) versus bilirubin/protein 
molar ratios. 
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Fig. 19 : The difference fluorescence emission 
spectra (AF) of Peak, (P,) ( A ) , Peak2 
(P2) (•) and Peak3 (P3) (O) obtained 
in tris-HCl buffer, pH 8.0., 1=0.06. 
The difference spectra were obtained 
by subtracting the fluorescence of 
bilirubin buffer and protein from the 
fluorescence of bilirubin-protein. 
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20 : Fluorescence emission spectra of PSA, DSA, HSA and GSA 
in 0.055 M sodium phosphate buffer, pH 8,0.,28°C at 
different bilirubin/albumin molar ratios in wavelength 
region of 500-600 nm. The bilirubin/albumin molar 
ratio from top to bottom were 1.0-.0.90, 0.80, 0.70, 
0.60, 0.50, 0.40, 0.30, 0.20, 0.10 and 0.0. The 
protein concentration was 2.5 uH. 
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Fig. 21 : Scatchard plots for the interaction of bilirubin with 
different albumins namely, PSA ( • ), DSA ( • ), HSA 
(O ) and GSA ( A ) . 
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TABLE V 
Binding parameters for the interaction of bilirubin with 
different albumins at pH 8.0, I = 0.15 at 28°C. 
Albumins Binding Constants Capacity 
(liters/mole) (n) 
PSA 4.41 x 107 0.83 
DSA 4.26 X 107 0.93 
BSA 1.72 x 107 0.89 
HSA 1.31 x 107 0.94 
GSA 1.21 x 107 0.97 
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(as taken from data of Fig. 11) is also included in 
Table V. It was found that among different serum 
albumins, the order of bilirubin binding with decreasing 
affinity was PSA (4.4xl07liters/mole), DSA 
(4.3xl07liters/mole), HSA (1.3xl07 liters/mole) and GSA 
(1.2xl07 liters/mole). 
Thus fluorescence properties of bilirubin-albumin 
complex can be used successfully to study the binding of 
bilirubin to albumin. 
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